Ken Griffin Enzo Biochem Inc Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Enzo Biochem Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 210,877 shares of ENZ stock, worth $115,982. This represents 0.0% of its overall portfolio holdings.

Number of Shares

210,877

Previous 18,300 1052.33%

Holding current value

$115,982

Previous $12,000 550.0%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$0.37 - $0.74 $61,020 - $122,041	164,921 Added 358.87%	210,877 $78,000
Q4 2024 Feb 14, 2025	BUY	$0.7 - $1.17 $13,553 - $22,653	19,362 Added 72.81%	45,956 $32,000
Q3 2024 Nov 14, 2024	BUY	$1.04 - $1.18 $27,657 - $31,380	26,594 New	26,594 $29,000
Q3 2023 Nov 14, 2023	BUY	$1.3 - $1.87 $1,674 - $2,408	1,288 Added 21.3%	7,334 $10,000
Q2 2023 Aug 14, 2023	SELL	$1.84 - $2.66 $30,980 - $44,786	-16,837 Reduced 73.58%	6,046 $11,000
Q1 2023 May 15, 2023	SELL	$1.0 - $2.51 $39,893 - $100,131	-39,893 Reduced 63.55%	22,883 $55,000
Q4 2022 Feb 14, 2023	BUY	$1.16 - $2.42 $51,718 - $107,895	44,585 Added 245.09%	62,776 $89,000
Q3 2022 Nov 14, 2022	SELL	$2.1 - $2.73 $21,575 - $28,048	-10,274 Reduced 36.09%	18,191 $40,000
Q2 2022 Aug 15, 2022	BUY	$2.0 - $3.0 $35,926 - $53,889	17,963 Added 171.04%	28,465 $59,000
Q1 2022 May 16, 2022	SELL	$2.9 - $3.47 $11,826 - $14,150	-4,078 Reduced 27.97%	10,502 $30,000
Q4 2021 Feb 14, 2022	SELL	$3.17 - $4.09 $127,963 - $165,101	-40,367 Reduced 73.47%	14,580 $46,000
Q3 2021 Nov 15, 2021	SELL	$3.01 - $3.77 $56,777 - $71,113	-18,863 Reduced 25.56%	54,947 $195,000
Q2 2021 Aug 16, 2021	BUY	$2.86 - $3.61 $82,962 - $104,718	29,008 Added 64.75%	73,810 $233,000
Q1 2021 May 17, 2021	BUY	$2.61 - $4.08 $45,327 - $70,857	17,367 Added 63.3%	44,802 $154,000
Q4 2020 Feb 16, 2021	SELL	$1.82 - $2.61 $42,975 - $61,629	-23,613 Reduced 46.26%	27,435 $69,000
Q3 2020 Nov 16, 2020	SELL	$2.02 - $3.02 $96,287 - $143,954	-47,667 Reduced 48.29%	51,048 $107,000
Q1 2020 May 15, 2020	BUY	$1.82 - $3.87 $61,374 - $130,504	33,722 Added 51.89%	98,715 $250,000
Q4 2019 Feb 14, 2020	SELL	$2.57 - $3.68 $137,554 - $196,964	-53,523 Reduced 45.16%	64,993 $171,000
Q3 2019 Nov 14, 2019	BUY	$3.01 - $4.0 $95,862 - $127,392	31,848 Added 36.75%	118,516 $426,000
Q2 2019 Aug 14, 2019	BUY	$2.79 - $4.31 $80,686 - $124,645	28,920 Added 50.08%	86,668 $292,000
Q1 2019 May 15, 2019	SELL	$2.54 - $4.02 $11,894 - $18,825	-4,683 Reduced 7.5%	57,748 $0
Q4 2018 Feb 14, 2019	SELL	$2.46 - $4.2 $76,004 - $129,763	-30,896 Reduced 33.11%	62,431 $173,000
Q3 2018 Nov 13, 2018	SELL	$3.81 - $5.53 $8,210 - $11,917	-2,155 Reduced 2.26%	93,327 $0
Q2 2018 Aug 10, 2018	SELL	$5.06 - $6.78 $13,145 - $17,614	-2,598 Reduced 2.65%	95,482 $0
Q1 2018 May 11, 2018	BUY	$5.43 - $8.36 $227,185 - $349,774	41,839 Added 74.39%	98,080 $538,000
Q4 2017 Feb 09, 2018	BUY	$8.15 - $10.55 $355,975 - $460,802	43,678 Added 347.67%	56,241 $458,000
Q3 2017 Nov 09, 2017	BUY	$10.45 - $11.44 $131,283 - $143,720	12,563	12,563 $132,000

Others Institutions Holding ENZ

# of Institutions

Shares Held

16.4M

Call Options Held

Put Options Held

View Full List

About ENZO BIOCHEM INC

Ticker ENZ
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 48,720,500
Market Cap $26.8M
Description
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. Th...

More about ENZ

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account